Current Hematologic Malignancy Reports

Papers
(The TQCC of Current Hematologic Malignancy Reports is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations86
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions38
Monoclonal Gammopathy-Associated Neuropathy28
Management of Chronic Myeloid Leukemia in Children and Young Adults24
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease22
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations18
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications17
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities17
Treatment-Free Remission: the New Goal in CML Therapy14
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer14
Value in Myeloma Care: Myth or Reality14
Challenges in Chronic Myeloid Leukemia Management in South America13
Targeting Apoptosis in ALL12
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses12
Transplantation and Cellular Therapy for Older Adults—The MSK Approach12
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic11
Prognostic and Predictive Models in Myelofibrosis11
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders10
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies10
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift10
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications10
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions9
How Do We Manage Chronic Lymphocytic Leukemia in India9
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)9
Multiple Myeloma: Current Clinical Landscape and Compounding Costs9
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia8
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia8
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults8
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies7
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders7
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center7
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma7
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies7
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia7
0.038562059402466